MR and cognitive testing of patients undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy

S. Roman-Goldstein, P. Mitchell, J. R. Crossen, P. C. Williams, A. Tindall, Edward Neuwelt

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

PURPOSE: To determine whether osmotic blood-brain barrier disruption is associated with MR abnormalities or cognitive deterioration and, if so, whether the MR findings correlate with cognitive test results. METHODS: Fifteen brain tumor patients who had a complete tumor response (nine central nervous system lymphoma, three germ cell and two astrocytoma, and one primitive neuroectodermal tumor) treated with blood-brain barrier disruption procedures (318 total procedures) with intraarterial chemotherapy were included. MR images were evaluated for the development of white matter hyperintensity, vascular lesions, or atrophy. Cognitive testing was performed to assess deterioration caused by this therapy. RESULTS: In two patients white matter hyperintensity developed, in two small vascular lesions developed, and in one mild atrophy developed. One infarct was asymptomatic and the second one resulted in mild dysesthesia in one upper extremity. No patient showed diminished cognitive function on the posttherapy evaluation. CONCLUSION: In patients undergoing blood-brain barrier disruption with intraarterial chemotherapy, new abnormalities on MR imaging may develop. These patients maintain the same level of cognitive and neurologic function and MR findings do not correlate with the results of cognitive testing.

Original languageEnglish (US)
Pages (from-to)543-553
Number of pages11
JournalAmerican Journal of Neuroradiology
Volume16
Issue number3
StatePublished - 1995

Fingerprint

Blood-Brain Barrier
Drug Therapy
Cognition
Atrophy
Blood Vessels
Primitive Neuroectodermal Tumors
Paresthesia
Astrocytoma
Germ Cells
Upper Extremity
Brain Neoplasms
Nervous System
Lymphoma
Central Nervous System
Neoplasms
White Matter
Therapeutics

Keywords

  • Blood-brain barrier
  • Brain, magnetic resonance
  • Chemotherapy
  • Iatrogenic disease or disorder

ASJC Scopus subject areas

  • Clinical Neurology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

MR and cognitive testing of patients undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy. / Roman-Goldstein, S.; Mitchell, P.; Crossen, J. R.; Williams, P. C.; Tindall, A.; Neuwelt, Edward.

In: American Journal of Neuroradiology, Vol. 16, No. 3, 1995, p. 543-553.

Research output: Contribution to journalArticle

Roman-Goldstein, S, Mitchell, P, Crossen, JR, Williams, PC, Tindall, A & Neuwelt, E 1995, 'MR and cognitive testing of patients undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy', American Journal of Neuroradiology, vol. 16, no. 3, pp. 543-553.
Roman-Goldstein, S. ; Mitchell, P. ; Crossen, J. R. ; Williams, P. C. ; Tindall, A. ; Neuwelt, Edward. / MR and cognitive testing of patients undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy. In: American Journal of Neuroradiology. 1995 ; Vol. 16, No. 3. pp. 543-553.
@article{3105178b450346bfad6c0ded4d9d5c77,
title = "MR and cognitive testing of patients undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy",
abstract = "PURPOSE: To determine whether osmotic blood-brain barrier disruption is associated with MR abnormalities or cognitive deterioration and, if so, whether the MR findings correlate with cognitive test results. METHODS: Fifteen brain tumor patients who had a complete tumor response (nine central nervous system lymphoma, three germ cell and two astrocytoma, and one primitive neuroectodermal tumor) treated with blood-brain barrier disruption procedures (318 total procedures) with intraarterial chemotherapy were included. MR images were evaluated for the development of white matter hyperintensity, vascular lesions, or atrophy. Cognitive testing was performed to assess deterioration caused by this therapy. RESULTS: In two patients white matter hyperintensity developed, in two small vascular lesions developed, and in one mild atrophy developed. One infarct was asymptomatic and the second one resulted in mild dysesthesia in one upper extremity. No patient showed diminished cognitive function on the posttherapy evaluation. CONCLUSION: In patients undergoing blood-brain barrier disruption with intraarterial chemotherapy, new abnormalities on MR imaging may develop. These patients maintain the same level of cognitive and neurologic function and MR findings do not correlate with the results of cognitive testing.",
keywords = "Blood-brain barrier, Brain, magnetic resonance, Chemotherapy, Iatrogenic disease or disorder",
author = "S. Roman-Goldstein and P. Mitchell and Crossen, {J. R.} and Williams, {P. C.} and A. Tindall and Edward Neuwelt",
year = "1995",
language = "English (US)",
volume = "16",
pages = "543--553",
journal = "American Journal of Neuroradiology",
issn = "0195-6108",
publisher = "American Society of Neuroradiology",
number = "3",

}

TY - JOUR

T1 - MR and cognitive testing of patients undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy

AU - Roman-Goldstein, S.

AU - Mitchell, P.

AU - Crossen, J. R.

AU - Williams, P. C.

AU - Tindall, A.

AU - Neuwelt, Edward

PY - 1995

Y1 - 1995

N2 - PURPOSE: To determine whether osmotic blood-brain barrier disruption is associated with MR abnormalities or cognitive deterioration and, if so, whether the MR findings correlate with cognitive test results. METHODS: Fifteen brain tumor patients who had a complete tumor response (nine central nervous system lymphoma, three germ cell and two astrocytoma, and one primitive neuroectodermal tumor) treated with blood-brain barrier disruption procedures (318 total procedures) with intraarterial chemotherapy were included. MR images were evaluated for the development of white matter hyperintensity, vascular lesions, or atrophy. Cognitive testing was performed to assess deterioration caused by this therapy. RESULTS: In two patients white matter hyperintensity developed, in two small vascular lesions developed, and in one mild atrophy developed. One infarct was asymptomatic and the second one resulted in mild dysesthesia in one upper extremity. No patient showed diminished cognitive function on the posttherapy evaluation. CONCLUSION: In patients undergoing blood-brain barrier disruption with intraarterial chemotherapy, new abnormalities on MR imaging may develop. These patients maintain the same level of cognitive and neurologic function and MR findings do not correlate with the results of cognitive testing.

AB - PURPOSE: To determine whether osmotic blood-brain barrier disruption is associated with MR abnormalities or cognitive deterioration and, if so, whether the MR findings correlate with cognitive test results. METHODS: Fifteen brain tumor patients who had a complete tumor response (nine central nervous system lymphoma, three germ cell and two astrocytoma, and one primitive neuroectodermal tumor) treated with blood-brain barrier disruption procedures (318 total procedures) with intraarterial chemotherapy were included. MR images were evaluated for the development of white matter hyperintensity, vascular lesions, or atrophy. Cognitive testing was performed to assess deterioration caused by this therapy. RESULTS: In two patients white matter hyperintensity developed, in two small vascular lesions developed, and in one mild atrophy developed. One infarct was asymptomatic and the second one resulted in mild dysesthesia in one upper extremity. No patient showed diminished cognitive function on the posttherapy evaluation. CONCLUSION: In patients undergoing blood-brain barrier disruption with intraarterial chemotherapy, new abnormalities on MR imaging may develop. These patients maintain the same level of cognitive and neurologic function and MR findings do not correlate with the results of cognitive testing.

KW - Blood-brain barrier

KW - Brain, magnetic resonance

KW - Chemotherapy

KW - Iatrogenic disease or disorder

UR - http://www.scopus.com/inward/record.url?scp=0028940851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028940851&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 543

EP - 553

JO - American Journal of Neuroradiology

JF - American Journal of Neuroradiology

SN - 0195-6108

IS - 3

ER -